Who We Are
We’re a HealthTech company founded by world-renowned team of visionary doctors to transform the future of healthcare by providing personalized care based on individualized risk assessment. Our initial focus is diabetic eye disease, one of the leading causes of blindness which can be prevented in over 90% of cases with early detection. The clinically validated RetinaRisk algorithm empowers patients and doctors alike by accurately calculating the risk of sight-threatening eye disease, while at the same time leading to efficiency and substantial savings in healthcare cost.
Our web based clinical decision support service enables easy access to risk management for diabetic eye care and can improve screening capacity by up to 60%. The iClinic also helps physicians motivate patients by visualizing and quantifying the future health effect of positive behavioral change today.
The RetinaRisk mobile app enables you to calculate your personalized risk of sight-threatening diabetic retinopathy, which is one of the leading causes of blindness in the world. Vision loss due to diabetes can be prevented in 90% of cases with early detection, timely treatment and preventive lifestyle changes. RetinaRisk can play a instrumental role in early detection by calculating the risk of diabetic eye disease and allowing users to understand which are the key underlying risk factors and which lifestyle changes can lower the risk.
The RetinaRisk API solution or Application Programming Interface, allows for a system-to-system connection to access the RetinaRisk algorithm, serving international healthcare providers, diabetes hospitals, ophthalmology clinics, diabetes platforms, pharmaceuticals and health insurers. The RetinaRisk API facilitates a truly personalized approach focused on providing the right treatment to the right patient at the right time.
Safe and efficient
EXTENSIVE CLINICAL VALIDATION
The RetinaRisk algorithm was developed by Dr. Einar Stefansson, Professor at the Department of Ophthalmology, University of Iceland and Dr. Arna Gudmundsdottir, Endocrinologist at the National Hospital Reykjavik, who have decades of experience in screening for diabetic retinopathy and treating diabetes. Our algorithm is based on extensive international research and has been clinically validated in over 25.000 diabetic patients in three continents and found to be robust.